SCHEMBL24288673

SCHEMBL24288673

CN(C(=O)CCCO)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CAMK2A Q9UQM7 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.34
GLS O94925 1/20 0.34
CYP4F2 P78329 2/20 0.33
CYP4A11 Q02928 2/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA4 P43681 1/20 0.32
GPR84 Q9NQS5 1/20 0.31
FFAR1 O14842 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
CNR1 P21554 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
KDM4E B2RXH2 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20738605 0.86 ALDH1A1 (0.31) ALDH1A1LMNAGLS
SCHEMBL19756267 0.80 ALDH1A1 (0.37) ALDH1A1LMNAGLSCHRNB2CHRNB4
SCHEMBL13888864 0.80 KDM4C (0.43) ALDH1A1GLS
SCHEMBL5205842 0.80 ALDH1A1 (0.37) ALDH1A1LMNAGLSCHRNB2CHRNB4
SCHEMBL13888860 0.78 KDM4C (0.50) ALDH1A1GLS
SCHEMBL19756278 0.78 ALDH1A1 (0.35) ALDH1A1LMNAGLSCHRNB2CHRNB4
SCHEMBL24288676 0.78 ALDH1A1 (0.50) ALDH1A1GPR84FFAR1FFAR4
SCHEMBL7553634 0.77 HDAC1 (0.35) ALDH1A1LMNAGLSHDAC1HDAC2
SCHEMBL18433422 0.77 ALDH1A1 (0.34) ALDH1A1LMNAGLS
SCHEMBL19756263 0.77 HDAC1 (0.35) ALDH1A1LMNAGLSCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820728-B2 Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids Acuitas Therapeutics, Inc. (CA) 2023-11-21 US disclosed
US-20220081392-A1 NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS Acuitas Therapeutics, Inc. (CA) 2022-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820728-B2 Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids TTPA, ACAA2, CPT2 CAMK2A 1323/4885ALDH1A1 207/4885LMNA 12/4885
US-20220081392-A1 NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS TTPA, ACAA2, POLRMT CAMK2A 1486/4885ALDH1A1 388/4885LMNA 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.